Free Republic

Drug maker Abbvie recently won a court case in which they sued Takeda Pharmaceutical, the company responsible for the production of their drug Lupron. In the case, Abbvie alleges that Takeda created a shortage of the drug by intermittently shutting down one of its plants. A judge found that Takeda Takeda was in breach of its contract with Abbvie and has ordered the to pay most of the $480.6 million it sought. Lupron may sound familiar to you because it has been at the center of the debate art whether or not children should be allowed to suppress puberty to...

American kids are in the grip of a gender contagion. New research from the Ethics and Public Policy Center reveals that the number of prescriptions for puberty blockers to under-18s doubled between 2017 and 2021. The data, based on information gathered from insurers, provide the clearest picture to date of the booming industry of gender butchery being practiced on American minors. In this medical Wild West, a well-oiled campaigning machine with tentacles into nonprofits, schools and even the White House recruits healthy kids and spits out sterilized simulacra of the opposite sex, often with lifelong health issues. Concerned parents, meanwhile,...

The Biden administration promoted the use of puberty blockers for transgender children by citing a study from an LGBT group funded in part by a manufacturer of the controversial drugs used in gender reassignment. In statements commemorating "Transgender Day of Visibility," the White House and Department of Health and Human Services cited research from the Trevor Project to support the use of puberty blockers, hormone therapy, and sex-reassignment procedures in children seeking to change genders. Two of the Trevor Project’s donors, AbbVie and Allergan, make drugs and medical products used in the medical gender transition process. The charitable foundations of...

Pharmaceutical giant AbbVie Inc. said it was re-evaluating its planned $54 billion acquisition of Shire PLC in light of new U.S. rules making it harder for American companies to lower taxes through overseas deal making. The rethink is the most dramatic fallout so far from a broad crackdown by Washington on so-called inversions—takeover deals structured to relocate tax domiciles of U.S. companies overseas to capture tax benefits.